Histological Response Rate After Mastectomy and Immediate Breast Reconstruction at the End of Neoadjuvant Chemotherapy and Radiotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

101 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-27

Study Completion Date

2025-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

At present, it is widely admitted not proposing immediate mammary reconstruction when an adjuvant radiotherapy is indicated because of the significant change of the cosmetic result (profit) and it whatever is the technique of reconstruction adopted. This is true all the more as it is about a reconstruction by prosthesis because of the prothetic died risk of hull(shell).

Teams proposed immediate mammary reconstructions to expanding (carrier) patients of carcinoma infiltrating, sometimes locally moved forward. For these patients, was not brought back(reported) by increase of the risk of local or remote relapse.

Two studies estimated afterward the feasibility of the mastectomy with immediate mammary reconstruction at the close of the chemotherapy and of the radiotherapy. The rate of morbidity is judged as acceptable. The rate of local second offense(recurrence) was similar to the patients benefiting from the classic therapeutic plan.

During an other study ( M-RIC), it was shown that the inversion of therapeutic sequence is possible and that by prescribing the chemotherapy and the radiotherapy before immediate mammary reconstruction, the morbidity is acceptable.

It is acquired that the chemotherapy néoadjuvant is equivalent to the post-operative chemotherapy as regards the global survival.

On the other hand, the rate of histological answer, according to subgroups, is very different. This rate can vary of 9 % for tumors RH +, negative Her2 in 45 % for tumors RH-, Her2 over expression. There are 33 % for the RH +, Her2 + and of 35 % for triple-negative.

The purpose of the investigators study is to estimate the rate of histological response during the inversion of therapeutic sequence to make sure of the oncologic safety(security), in particular by molecular subgroups, considering the heterogeneousness of the results(profits) after chemotherapy néoadjuvant only. Sataloff and Chevallier Classifications is the references and will be used here, but the investigators can also use Symmans classification in addition.

The rate of local and metastatic second offenses(recurrences) will also be estimated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Breast Reconstruction Following Breast Cancer in Very High Risk Patients

NCT03261323

Breast Cancer Malignant Neoplasm of Breast

WITHDRAWN NA

Radiotherapy After Mastectomy for Breast Cancer Patients at Increased Risk of Local Recurrence

NCT03101683

Breast Cancer

UNKNOWN NA

Neoadjuvant Radiotherapy and Immediate Implant-Based Breast Reconstruction

NCT05992870

Breast Cancer Implant Breast Reconstruction Neoadjuvant Radiotherapy

RECRUITING NA

Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT

NCT01664091

Breast Cancer

COMPLETED NA

Evaluation of Two Boost Radiation Schedules in Post Lumpectomy Early Stage Carcinoma Breast

NCT02142907

Breast Cancer Adverse Effect of Radiation Therapy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immediate Mammary Reconstruction

Chemotherapy, radiation therapy, mastectomy with immediate mammary reconstruction

Group Type EXPERIMENTAL

Immediate mammary reconstruction

Intervention Type PROCEDURE

Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.

Chemotherapy

Intervention Type DRUG

Chemotherapy treatment

Radiation therapy

Intervention Type RADIATION

Radiation therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immediate mammary reconstruction

Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.

Intervention Type PROCEDURE

Chemotherapy

Chemotherapy treatment

Intervention Type DRUG

Radiation therapy

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

anthracyclines and taxotere with or without Herceptin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years,
* Infiltrating carcinoma,
* Neoadjuvant chemotherapy indication,
* Radiotherapy indication,
* 0 or 1 score Performance status (WHO),
* Signed informed consent,
* Affiliation to Social Security System

Exclusion Criteria

* Lobular carcinoma,
* "Luminal A" Tumor (RH+ and Her2 negative with grade I, and tumor RH+ Her2 negative with grade II and with Ki67\<20%),
* Attempt of first conservative treatment,
* Metastatic breast cancer,
* Inflammatory carcinoma,
* History of homolateral or controlateral mammary carcinoma,
* Progression disease (despite neoadjuvant chemotherapy),
* Contraindications in an immediate mammary reconstruction by scrap of big dorsal (comorbidity),
* Any psychological, familial, sociological or geographical condition-potentially hampering compliance with the study protocol or follow-up schedule,
* Patients deprived of liberty or placed under the authority of a tutor.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No